文献速递肾癌与肾肿瘤

高危非透明细胞肾细胞癌术后复发模式与监测启示:ECOG-ACRIN E2805 亚组分析

Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
PubMed 文献 · J Urol · 2019-01-01

该研究回顾性分析 E2805 试验中 403 例完全切除的高危非透明细胞肾细胞癌患者,术后接受最多 54 周舒尼替尼、索拉非尼或安慰剂治疗并标准化影像监测 10 年。中位随访 6.2 年,36% 复发;非透明细胞癌 5 年复发率 34.6%(95%CI 29.8-39.4),与透明细胞癌 39.5%(95%CI 36.9-42.1)相当,但腹部复发更多(26.4% vs 18.2%,p=0.0008)、胸部复发更少(13.7% vs 20.9%,p=0.0005)。现行监测指南可捕获约 90% 的任何部位复发。

要点

  • 非透明细胞肾癌术后 5 年复发率与透明细胞癌相当。
  • 非透明细胞肾癌腹部复发风险更高,胸部复发风险更低。
  • 现行监测指南可捕获约 90% 的任何部位复发,强调横断面长期影像。

核心结论

  • 非透明细胞肾细胞癌可能具有不同于透明细胞肾细胞癌的复发模式。
  • 研究结果强调对高危、已切除的非透明细胞肾细胞癌患者进行横断面长期影像监测的重要性。

研究设计与样本

  • 回顾性分析 III 期 ECOG-ACRIN E2805 试验中完全切除的非透明细胞肾细胞癌患者记录。
  • 共纳入 403 例非透明细胞肾细胞癌患者,术后接受最多 54 周舒尼替尼、索拉非尼或安慰剂治疗。
  • 按标准化间隔进行影像监测,随访 10 年;采用累积发生率估计复发率并考虑竞争风险。

主要发现

  • 中位随访 6.2 年,36% 的非透明细胞肾细胞癌患者复发。
  • 在 1,541 例患者中,非透明细胞癌与透明细胞癌 5 年复发率分别为 34.6%(95%CI 29.8-39.4)和 39.5%(95%CI 36.9-42.1)。
  • 非透明细胞癌患者腹部复发显著更多(5 年复发率 26.4% vs 18.2%,p=0.0008),胸部复发显著更少(13.7% vs 20.9%,p=0.0005)。
  • 现行监测指南可潜在捕获约 90% 的任何部位复发。

临床怎么用

  • 对高危、已切除的非透明细胞肾细胞癌患者,应重视腹部横断面长期影像监测。
  • 现行监测指南可捕获约 90% 的任何部位复发,但需关注非透明细胞癌腹部复发风险更高的特点。

局限性

  • 本研究为回顾性分析。
  • 研究对象为 E2805 试验中接受术后辅助治疗的高危患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The natural history of nonclear cell renal cell carcinoma following surgery with curative intent remains poorly defined with postoperative surveillance informed by guidelines largely intended for clear cell renal cell carcinoma. We evaluated relapse patterns and potential implications for post-nephrectomy surveillance in patients with nonclear cell renal cell carcinoma enrolled in the E2805 trial, the largest randomized trial of adjuvant antiangiogenic therapy of high risk renal cell carcinoma. MATERIALS AND METHODS: We retrospectively analyzed the records of patients with completely resected nonclear cell renal cell carcinoma. Participants received up to 54 weeks of postoperative therapy with sunitinib, sorafenib or placebo and underwent surveillance imaging at standardized intervals for 10 years. For recurrence rates by site the cumulative incidence was estimated, accounting for competing risks. The adequacy of strict adherence to post-nephrectomy surveillance guidelines was evaluated. RESULTS: A total of 403 patients with nonclear cell renal cell carcinoma were enrolled in the study. During a median followup of 6.2 years 36% of nonclear cell renal cell carcinomas recurred. Five-year recurrence rates were comparable for nonclear and clear cell renal cell carcinoma in the 1,541 patients, including 34.6% (95% CI 29.8-39.4) and 39.5% (95% CI 36.9-42.1), respectively. However, patients with nonclear cell renal cell carcinoma were significantly more likely to have abdominal sites of relapse (5-year recurrence rate 26.4% vs 18.2%, p = 0.0008) and significantly less likely to experience relapse in the chest (5-year recurrence rate 13.7% vs 20.9%, p = 0.0005). Current surveillance guidelines would potentially capture approximately 90% of relapses at any site. CONCLUSIONS: Nonclear cell renal cell carcinoma may show a distinct pattern of relapse compared to clear cell renal cell carcinoma. Our findings emphasize the importance of cross-sectional, long-term imaging in patients with high risk, resected, nonclear cell renal cell carcinoma.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Narayan V, Puligandla M, Haas NB, et al. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial. J Urol. 2019. PMID: 30130544. doi:10.1016/j.juro.2018.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。